Aktis Oncology
AKTS on Nasdaq. Aktis Oncology develops radiopharmaceuticals that deliver radioisotopes to tumors in cancer patients. Market value $908m.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
What to watch out for
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.
$16.15 a share, 16% above its 1-year low
Over the past year the price has ranged from $13.96 to $34.19.
Prices from Friday’s close (20 November).
Five years of cash, in billions
Five-year fundamentals are not available yet.
Health checks
- Free cash flow positiveNot enough data
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Not enough data
- DebtUnknown
- Revenue growth, five yearsUnknown
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 March 2026
- Next quarterly (estimated, 10-Q)
- 11 February 2027
Who owns it
1 long-term investor we follow owns it, up from 0 last quarter. 114 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Polen CapitalDan Davidowitz | $2m | <0.1% | New |
Largest holders overall
- MPM Bioimpact$156m
- EcoR1 Capital$155m
- Blue Owl Capital Holdings LP$99mCut
- BlackRock$73mAdded
- T. Rowe Price Investment Management$66mCut
- Wellington Management Group LLP$63mCut
- RTW Investments, LP$51m
- RA Capital Management, L.P.$42mCut
- Jupiter Topco$42m
- Baker Bros. Advisors LP$32m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- ANSBERT GADICKEPassive investorat least 19.3%(filed with 12 related holders)Since 12 January 2026
What they said
The MPM Entities acquired the securities reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to…
Read the filing - Eli Lilly and CompanyPassive investor11.9%Since 12 January 2026
What they said
The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to…
Read the filing - VV Manager II LLCPassive investorat least 10.9%(filed with 3 related holders)Since 12 January 2026
What they said
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other…
Read the filing - EcoR1 Capital, LLCPassive investorat least 9.1%(filed with 2 related holders)Since 12 January 2026
What they said
Oleg Nodelman, the manager of EcoR1, is a member of the Issuer's board of directors. The reporting persons acquired securities of the Issuer for investment purposes based on their belief that the Issuer's securities represented an attractive investment opportunity. The reporting…
Read the filing - T. Rowe Price Investment Management, Inc.Passive investor6.2%Since 30 September 2026
- Blue Owl Capital Holdings LPPassive investor5.9%Since 31 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
ANSBERT GADICKE Passive investor | at least 19.3% (filed with 12 related holders) | 12 January 2026 | What they saidThe MPM Entities acquired the securities reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to… Read the filing |
Eli Lilly and Company Passive investor | 11.9% | 12 January 2026 | What they saidThe Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to… Read the filing |
VV Manager II LLC Passive investor | at least 10.9% (filed with 3 related holders) | 12 January 2026 | What they saidThe information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other… Read the filing |
EcoR1 Capital, LLC Passive investor | at least 9.1% (filed with 2 related holders) | 12 January 2026 | What they saidOleg Nodelman, the manager of EcoR1, is a member of the Issuer's board of directors. The reporting persons acquired securities of the Issuer for investment purposes based on their belief that the Issuer's securities represented an attractive investment opportunity. The reporting… Read the filing |
T. Rowe Price Investment Management, Inc. Passive investor | 6.2% | 30 September 2026 | |
Blue Owl Capital Holdings LP Passive investor | 5.9% | 31 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $59m of shares on the open market. 3 sold $3m, $258,621 of it under preset trading plans.
- Czibere AkosChief Medical OfficerSoldunder a preset trading plan
- Date
- 23 September 2026
- Shares
- 12,500
- Price
- $20.69
- Value
- $258,621
- Herrmann KenDirectorSold
- Date
- 20 July 2026
- Shares
- 4,856
- Price
- $24.56
- Value
- $119,274
- Herrmann KenDirectorSold
- Date
- 17 July 2026
- Shares
- 3,065
- Price
- $25.21
- Value
- $77,259
- Ron-Bigger ShulamitChief Operating OfficerSold
- Date
- 8 July 2026
- Shares
- 50,000
- Price
- $27.75
- Value
- $1m
- Czibere AkosChief Medical OfficerSold
- Date
- 8 July 2026
- Shares
- 50,000
- Price
- $27.77
- Value
- $1m
- Foley ToddDirectorBought
- Date
- 12 January 2026
- Shares
- 232,870
- Price
- $18.00
- Value
- $4m
- Kim Helen SusanDirectorBought
- Date
- 12 January 2026
- Shares
- 835,000
- Price
- $18.00
- Value
- $15m
- NODELMAN OLEGDirectorBought
- Date
- 12 January 2026
- Shares
- 2,222,222
- Price
- $18.00
- Value
- $40m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 23 September 2026 | Czibere Akos Chief Medical Officer | Sold under a preset trading plan | 12,500 | $20.69 | $258,621 |
| 20 July 2026 | Herrmann Ken Director | Sold | 4,856 | $24.56 | $119,274 |
| 17 July 2026 | Herrmann Ken Director | Sold | 3,065 | $25.21 | $77,259 |
| 8 July 2026 | Ron-Bigger Shulamit Chief Operating Officer | Sold | 50,000 | $27.75 | $1m |
| 8 July 2026 | Czibere Akos Chief Medical Officer | Sold | 50,000 | $27.77 | $1m |
| 12 January 2026 | Foley Todd Director | Bought | 232,870 | $18.00 | $4m |
| 12 January 2026 | Kim Helen Susan Director | Bought | 835,000 | $18.00 | $15m |
| 12 January 2026 | NODELMAN OLEG Director | Bought | 2,222,222 | $18.00 | $40m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 4 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.